Cyclacel Pharmaceuticals (NASDAQ:CYCC) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC) in a research report released on Wednesday. The brokerage issued a sell rating on the biotechnology company’s stock.

Cyclacel Pharmaceuticals Price Performance

CYCC opened at $0.23 on Wednesday. The company has a market capitalization of $46.88 million, a price-to-earnings ratio of -0.02 and a beta of 0.15. The business’s 50-day moving average price is $0.29 and its two-hundred day moving average price is $0.43. Cyclacel Pharmaceuticals has a 1 year low of $0.17 and a 1 year high of $4.00.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last released its earnings results on Wednesday, April 2nd. The biotechnology company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.04). The firm had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.01 million. Cyclacel Pharmaceuticals had a negative net margin of 18,150.00% and a negative return on equity of 1,901.11%.

Insider Buying and Selling at Cyclacel Pharmaceuticals

In other news, CEO David E. Lazar sold 194,628,820 shares of the stock in a transaction dated Wednesday, February 26th. The shares were sold at an average price of $0.03, for a total transaction of $5,838,864.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 68.00% of the company’s stock.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.